StockData
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc. (SER) stock

SERNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$1.41−0.09 (-6.00%)

Close on Nov 12, 2026Market cap $35.81MP/E –Yield –

Serina Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Serina Therapeutics's gross margin for the twelve months ending Dec 31, 2023 was 3.2%. For fiscal 2023 it was 3.2%, against 61.8% the year before. The highest annual figure on record is 92.8% in fiscal 2020.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 20233.2%−58.5
FY2022Dec 31, 202261.8%−25.0
FY2021Dec 31, 202186.8%−6.0
FY2020Dec 31, 202092.8%+6.9
FY2019Dec 31, 201985.9%+12.0
FY2018Dec 31, 201873.9%−14.1
FY2017Dec 31, 201788.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2023Dec 31, 20231.8%−85.7
Q3 FY2023Sep 30, 2023117.2%+72.8
Q2 FY2023Jun 30, 202357.1%+7.1
Q1 FY2023Mar 31, 202330.0%−50.0
Q4 FY2022Dec 31, 202287.5%−8.8
Q3 FY2022Sep 30, 202244.4%−47.2
Q2 FY2022Jun 30, 202250.0%−14.9
Q1 FY2022Mar 31, 202280.0%−14.6
Q4 FY2021Dec 31, 202196.3%−0.5
Q3 FY2021Sep 30, 202191.7%+16.3
Q2 FY2021Jun 30, 202164.9%−28.5
Q1 FY2021Mar 31, 202194.6%−4.2
Q4 FY2020Dec 31, 202096.8%+11.2
Q3 FY2020Sep 30, 202075.4%−12.7
Q2 FY2020Jun 30, 202093.3%+7.3
Q1 FY2020Mar 31, 202098.9%+15.1
Q4 FY2019Dec 31, 201985.6%+43.1
Q3 FY2019Sep 30, 201988.1%−13.0
Q2 FY2019Jun 30, 201986.1%+3.1
Q1 FY2019Mar 31, 201983.8%+29.4
Q4 FY2018Dec 31, 201842.5%–
Q3 FY2018Sep 30, 2018101.1%–
Q2 FY2018Jun 30, 201883.0%–
Q1 FY2018Mar 31, 201854.4%–

More Serina Therapeutics figures

See a number that looks wrong?